Law S W, Lackner K J, Fojo S S, Hospattankar A, Monge J C, Brewer H B
Adv Exp Med Biol. 1986;201:151-62. doi: 10.1007/978-1-4684-1262-8_14.
The application of molecular biology techniques has enabled us to determine the gene sequence, organization, transcription and processing of apolipoprotein genes. Consequently, new insights have been gained in the biosynthesis and processing of these proteins. In addition to apoA-I, apoA-II and apoC-III reported here, other apolipoprotein genes such as apoC-II and apoE genes were found to share common intron-exon organizations. The results suggest that these genes most probably arise from a common ancestral gene. Utilizing cDNA as hybridization probes, we have localized apoA-I, apoA-II, apoC-II, apoC-III, apoE and apoB to specific locations of individual chromosomes (for review, see ref. 6). There is no clear relationship between currently known physiological function and the organization of the apolipoproteins in the chromosomes with the exception of the LDL receptor and its ligand, apoE which are localized to chromosome 19. However, apoB-100, the major ligand for the LDL receptor is on chromosome 2 and not in synteny with the apoE and the LDL receptor genes. The cloning of the major human apolipoprotein genes have also allowed us to initiate studies on the molecular defects leading to various dyslipoproteinemias including Tangier disease and abetalipoproteinemia. Undoubtedly, information derived from these studies will provide the basis for future in vitro and in vivo studies on patients with dyslipoproteinemia and premature atherosclerosis.
分子生物学技术的应用使我们能够确定载脂蛋白基因的序列、结构、转录和加工过程。因此,在这些蛋白质的生物合成和加工方面有了新的认识。除了本文报道的载脂蛋白A-I、载脂蛋白A-II和载脂蛋白C-III外,还发现其他载脂蛋白基因,如载脂蛋白C-II和载脂蛋白E基因,具有共同的内含子-外显子结构。结果表明,这些基因很可能起源于一个共同的祖先基因。利用cDNA作为杂交探针,我们已将载脂蛋白A-I、载脂蛋白A-II、载脂蛋白C-II、载脂蛋白C-III、载脂蛋白E和载脂蛋白B定位到各条染色体的特定位置(综述见参考文献6)。除了定位在19号染色体上的低密度脂蛋白受体及其配体载脂蛋白E外,目前已知的生理功能与染色体上载脂蛋白的结构之间没有明确的关系。然而,低密度脂蛋白受体的主要配体载脂蛋白B-100位于2号染色体上,与载脂蛋白E和低密度脂蛋白受体基因不在同一条染色体上。主要人类载脂蛋白基因的克隆也使我们能够开始研究导致各种脂蛋白异常血症(包括Tangier病和无β脂蛋白血症)的分子缺陷。毫无疑问,从这些研究中获得的信息将为未来对脂蛋白异常血症和早发性动脉粥样硬化患者进行的体外和体内研究提供基础。